Abstracts from four Hoosier Cancer Research Network studies have been accepted by the American Society of Clinical Oncology (ASCO) for the 2015 Annual Meeting in Chicago on May 29 – June 2. The studies include GU10-148 (poster discussion), BRE09-146 (poster), GI05-102 (poster), and QL12-153 (publication-only abstract).

GU10-148
Abstract #4586; Poster Board #187
Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). Read more.

BRE09-146
Abstract #1082; Poster Board #196
Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. Read more.

GI05-102
Abstract #3618; Poster Board #111
Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Read more.

QL12-153
Abstract #e20737 (Publication-only abstract, published in conjunction with the 2015 ASCO Annual Meeting, but not presented at the meeting.)
Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study. Read more.

HCRN will once again have a booth during ASCO. The HCRN booth is #21163 and is located across from the Food Court in McCormick Place South, Exhibit Hall A.

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network (formerly known as Hoosier Oncology Group) conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has initiated more than 150 trials in a variety of cancer types and supportive care, resulting in more than 300 publications. More than 4,600 subjects have participated in Hoosier Cancer Research Network clinical trials.